Skip to main content
Livermore
Livermore
ZHEN

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Holders of 5% or more of AMLX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Amylyx Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AMLX
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G10.70%11.4M sharesNewOct 7, 20251 filingOct 7, 2025SEC
Perceptive Advisors LLC13G/A8.20%8.95M shares−0.60 ppfrom 8.80%Feb 14, 20253 filingsNov 14, 2025SEC
Adage Capital Management, L.P.13G/A6.39%6.82M shares−3.48 ppfrom 9.87%May 12, 20253 filingsNov 13, 2025SEC
BlackRock, Inc.13G5.50%4.92M sharesNewJul 17, 20251 filingJul 17, 2025SEC
Commodore Capital LP13G5.10%5.65M sharesNewNov 17, 20251 filingNov 17, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

17 Schedule 13D and 13G filings on Amylyx Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AMLX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 26, 20263:41 PM ETVanguard Group Inc13G/A0.00%0 shares−4.94 ppfrom 4.94%Below 5%Mar 13, 2026SEC
Nov 17, 20255:39 PM ETCommodore Capital LPand 3 others13G5.10%5.65M sharesNewNov 10, 2025SEC
Nov 14, 20254:10 PM ETPoint72 Asset Management, L.P.and 2 others13G/A2.60%2.80M shares−2.70 ppfrom 5.30%Below 5%Sep 30, 2025SEC
Nov 14, 20254:00 PM ETPerceptive Advisors LLCand 2 others13G/A8.20%8.95M shares−0.60 ppfrom 8.80%Sep 30, 2025SEC
Nov 13, 20259:05 AM ETAdage Capital Management, L.P.and 2 others13G/A6.39%6.82M shares−3.48 ppfrom 9.87%Sep 30, 2025SEC
Oct 30, 20252:37 PM ETVanguard Group Inc13G/A4.94%5.27M shares−0.10 ppfrom 5.04%Below 5%Sep 30, 2025SEC
Oct 7, 20253:49 PM ETFMR LLCand 1 other13G10.70%11.4M sharesNewSep 30, 2025SEC
Aug 12, 20259:07 AM ETAdage Capital Management, L.P.and 2 others13G/A9.87%8.80M shares+3.44 ppfrom 6.43%Jun 30, 2025SEC
Jul 29, 202511:21 AM ETVanguard Group Inc13G5.04%4.50M sharesNewJun 30, 2025SEC
Jul 17, 20257:44 PM ETBlackRock, Inc.13G5.50%4.92M sharesNewJun 30, 2025SEC
Jun 25, 20255:24 PM ETPoint72 Asset Management, L.P.and 2 others13G5.30%4.72M shares+4.10 ppfrom 1.20%Jun 24, 2025SEC
May 15, 20254:30 PM ETPerceptive Advisors LLCand 2 others13G/A8.80%7.87M shares+0.90 ppfrom 7.90%Mar 31, 2025SEC
May 15, 20253:52 PM ETPoint72 Asset Management, L.P.and 2 others13G/A1.20%1.05M shares−4.40 ppfrom 5.60%Below 5%Mar 31, 2025SEC
May 12, 20259:05 AM ETAdage Capital Management, L.P.and 2 others13G6.43%5.70M sharesNewMar 31, 2025SEC
Feb 14, 20254:30 PM ETPanacea Innovation Ltdand 3 others13G/A2.60%2.20M shares–Below 5%Dec 31, 2024SEC
Feb 14, 20254:15 PM ETPerceptive Advisors LLCand 2 others13G/A7.90%6.77M shares–Dec 31, 2024SEC
Jan 14, 20254:53 PM ETPoint72 Asset Management, L.P.and 2 others13G5.60%4.82M sharesNewJan 13, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Amylyx Pharmaceuticals, Inc. shares.

No Form 144 notices for Amylyx Pharmaceuticals, Inc. are on file.